Arcadia Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(10,651) | $(1,859) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of common stock warrant and option liabilities | (4,274) | (1,314) |
| Change in fair value of contingent consideration | — | (2,000) |
| Issuance and offering costs | 1,072 | — |
| Valuation loss on June 2026 PIPE | 5,423 | — |
| Loss on January 2026 Inducement Offer | 2,877 | — |
| Depreciation | 8 | 28 |
| Lease amortization | — | 117 |
| Amortization of note receivable | — | (69) |
| Gain on sale of intangible assets | — | (750) |
| Gain on receipt of Above Food Ingredients, Inc. common stock | — | (1,067) |
| Unrealized loss subsequent to receipt of Above Food Ingredients, Inc. common stock | 4,304 | — |
| Stock-based compensation | 29 | 164 |
| Credit loss | — | 4,489 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other receivables | (134) | (417) |
| Inventories | 282 | (585) |
| Prepaid expenses and other current assets | 84 | 544 |
| Other noncurrent assets | — | (56) |
| Accounts payable and accrued expenses | (431) | (630) |
| Amounts due to related parties | — | (30) |
| Other current liabilities | (7) | (57) |
| Operating lease liabilities | — | (129) |
| Net cash used in operating activities | (1,418) | (3,621) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of intangible assets | — | 750 |
| Net cash provided by investing activities | — | 750 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from June 2026 PIPE | 4,000 | — |
| Payments of offering costs relating to June 2026 PIPE | (395) | — |
| Proceeds from January 2026 Inducement Offer | 2,082 | — |
| Payments of offering costs relating to January 2026 Inducement Offer | (350) | — |
| Proceeds from ESPP purchases | — | 5 |
| Net cash provided by financing activities | 5,337 | 5 |
| Net increase (decrease) in cash and cash equivalents | 3,919 | (2,866) |
| Cash and cash equivalents — beginning of period | 259 | 4,242 |
| Cash and cash equivalents — end of period | $4,178 | $1,376 |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Accrued legal fees included in offering costs related to June 2026 PIPE | $55 | $— |
| Preferred investment options issued to placement agent and included in offering costs related to June 2026 PIPE | $201 | $— |
| Preferred investment options issued to placement agent and included in offering costs related to January 2026 Inducement Offer | $71 | $— |
| Warrant and option modifications included in Loss on January 2026 Inducement Offer | $555 | $— |
| Fair value of Above Food Ingredients, Inc. common stock received | $— | $3,067 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.